At FDA, Graham is still the whistle-blower – USA Today Thu, 17 Nov 2005 On Nov. 18, 2004, Dr. David Graham, FDA’s associate director for science and medicine, blew the whistle in testimony before the Senate Finance Committee, on FDA’s “profound regulatory failure” to protect the public against lethal prescription…
Rutherford Institute Interview: Allen Jones reveals TMAP drug scam linked to then Governor George W. Bush Fri, 14 Oct 2005 An in-depth interview by John Whitehead of the Rutherford Institute with Allen Jones,*a former inspector with the Pennsyvania Office of Inspector General, who initially blew the whistle on Pennsylvania’s version…
APA Under the Influence of PhaRma June 5, 2002 FYI Reporters who attended the 2002 annual convention of the American Association of Psychiatry / PhaRma have had a rude awakening about the scope of industry’s influence. Essentially, psychiatrists are drug marketers for industry, helping to create blockbuster sales: Â Even…
$95 billion a year spent on medical research in US – JAMA Fri, 23 Sep 2005 A special issue of the Journal of the American Medical Association, JAMA, focuses on medical research spending and findings. A study that examined US spending for medical research—$95 billion approaching $100 billion–57% is spent…
SAMHSA Backs Away From TeenScreen & TMAP Mon, 24 Oct 2005 On October 17, a meeting took place with Charles Currie in Washington DC – with some in attendance by conference call. Currie is the Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA), the federal agency charged…
Schizophrenia drugs increase diabetes risk Fri, 29 Aug 2003 A large scale study by the Veterans Administration corroborates a body of evidence demonstrating that the much touted “improved” newer drugs for the treatment of schizophrenia–Zyprexa, Risperdal, Seroquesl– are precipitating the onset of diabetes at alarming rates– especially among younger patients….
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP Sun, 23 Oct 2005 An investigation by the journal, NATURE (the largest of its kind) reveals that not only do conflicts of interest taint the conduct and outcome of clinical trials, the authors who formulate…
Medication switched for research purposes – patient nearly dies Tue, 11 Nov 2003 The Boston Globe reports that an investigation by a state oversight agency, “uncovered numerous ethical violations at the Solomon Carter Fuller Mental Health Center by Boston Medical Center physicians contracted to treat patients there.” Boston University Medical…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Philadelphia Daily News Pharma Influence: Penn Psychiatrist Files Whistleblower Lawsuit – Investigtion Confirms Medicare Chief Lied to Congress Wed, 7 Jul 2004 “Drug companies not only write checks to hospitals, they write checks to politicians…They write checks to both sides of the aisle.” Two separate news reports provide a glimpse…
